The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Regional differences in patient (pt) characteristics of AVAGAST: An exploratory comparison in chemotherapy plus placebo (PL) arm between Japanese (JPN) and the rest of the world (ROW) pts.
Tomohira Nishina
Honoraria - Chugai Pharma
Akira Sawaki
No relevant relationships to disclose
Kensei Yamaguchi
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Merck Serono
Toshihiko Doi
No relevant relationships to disclose
Yasuhide Yamada
Research Funding - Chugai Pharma
Keisho Chin
No relevant relationships to disclose
Taroh Satoh
No relevant relationships to disclose
Narikazu Boku
Honoraria - Ono Pharmaceutical ; Taiho Pharmaceutical; Takeda
Research Funding - Taiho Pharmaceutical
Yasushi Omuro
No relevant relationships to disclose
Yoshito Komatsu
No relevant relationships to disclose
Hiroya Takiuchi
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Yasuo Hamamoto
No relevant relationships to disclose
Wasaburo Koizumi
No relevant relationships to disclose
Shigehira Saji
No relevant relationships to disclose
Manish A. Shah
Consultant or Advisory Role - Genentech
Eric Van Cutsem
Research Funding - Roche
Yoon-Koo Kang
Consultant or Advisory Role - Roche
Honoraria - Roche
Atsushi Ohtsu
Honoraria - Chugai Pharma; Novartis; Taiho Pharmaceutical